Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status

Verfasser / Beitragende:
[Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Shunsuke Hamada, Eiji Kozawa, Kunihiro Ikuta, Yuichi Ando, Naoki Ishiguro]
Ort, Verlag, Jahr:
2015
Enthalten in:
International Journal of Clinical Oncology, 20/6(2015-12-01), 1211-1217
Format:
Artikel (online)
ID: 605490740
LEADER caa a22 4500
001 605490740
003 CHVBK
005 20210128100506.0
007 cr unu---uuuuu
008 210128e20151201xx s 000 0 eng
024 7 0 |a 10.1007/s10147-015-0829-0  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10147-015-0829-0 
245 0 0 |a Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status  |h [Elektronische Daten]  |c [Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Shunsuke Hamada, Eiji Kozawa, Kunihiro Ikuta, Yuichi Ando, Naoki Ishiguro] 
520 3 |a Background: This study was conducted to determine the efficacy and safety of low-dose chemotherapy with methotrexate (MTX) and vinblastine (VBL) for patients with desmoid tumors refractory to meloxicam treatment, focusing in particular on the relationship between the efficacy of this chemotherapy and catenin β-1 (CTNNB1) mutation status. Patients and methods: Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution. Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week. The responses of all patients were evaluated, and factors that were correlated with efficacy were analyzed, including CTNNB1 mutation status. Results: Sixty-eight patients were prospectively treated with meloxicam. MTX+VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression. A few patients showed grade 3-4 treatment-related toxicity with the administration of MTX and VBL every other week. Intriguingly, CTNNB1 status did not affect the efficacy of this treatment. Conclusion: MTX and VBL treatment every other week is well tolerated and achieved a favorable response in patients resistant to meloxicam treatment, regardless of CTNNB1 mutation status. 
540 |a Japan Society of Clinical Oncology, 2015 
690 7 |a Desmoid tumor  |2 nationallicence 
690 7 |a CTNNB1  |2 nationallicence 
690 7 |a Methotrexate  |2 nationallicence 
690 7 |a Vinblastine  |2 nationallicence 
700 1 |a Nishida  |D Yoshihiro  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
700 1 |a Tsukushi  |D Satoshi  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
700 1 |a Urakawa  |D Hiroshi  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
700 1 |a Hamada  |D Shunsuke  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
700 1 |a Kozawa  |D Eiji  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
700 1 |a Ikuta  |D Kunihiro  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
700 1 |a Ando  |D Yuichi  |u Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Japan  |4 aut 
700 1 |a Ishiguro  |D Naoki  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
773 0 |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/6(2015-12-01), 1211-1217  |x 1341-9625  |q 20:6<1211  |1 2015  |2 20  |o 10147 
856 4 0 |u https://doi.org/10.1007/s10147-015-0829-0  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10147-015-0829-0  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Nishida  |D Yoshihiro  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tsukushi  |D Satoshi  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Urakawa  |D Hiroshi  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Hamada  |D Shunsuke  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kozawa  |D Eiji  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ikuta  |D Kunihiro  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ando  |D Yuichi  |u Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ishiguro  |D Naoki  |u Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/6(2015-12-01), 1211-1217  |x 1341-9625  |q 20:6<1211  |1 2015  |2 20  |o 10147